Medicare's first step in reining in the skyrocketing cost of specialty drugs deserves support—something it has not received from hospitals, doctors, politicians or, of course, the pharmaceutical industry, which benefits the most from the status quo.
The horrific events in Orlando in the early hours of June 12 remind us once again of the cowardly failure of our political leaders over many years to take action against America's No. 1 public health crisis.
In the year 2016, we have a major party candidate proclaiming from a public podium that an Indiana-born judge cannot preside fairly over a trial because of his Mexican heritage. This is racism pure and simple.
Healthcare providers shouldn't let the good news on shrinking bad debt distract them from dealing with one of the more pressing financial issues facing the industry—helping people saddled with unmanageable bills.
Obamacare's enemies are gearing up to make rising health insurance premiums a major attack point during the coming election season, but the public needs to consider the real reasons behind the higher prices.
While the latest cancer drugs emerging from drug and biotechnology company labs can come with hefty price tags, they don't necessarily have a lot of evidence showing they actually work.
President Obama's upcoming visit to Hiroshima in pursuit of a nuclear weapon-free world will unleash uncomfortable emotions on both sides of the Pacific. He ought to note what survivors of the blast taught mankind about the long-term effects of radiation exposure and the threat posed by nuclear war.
In most presidential election years, the politics of healthcare at least has a nodding acquaintance with reality. This year, the two aren't even on speaking terms.
It was a field day last week for health wonks in Washington. The CMS issued two major rules—one final, one proposed—that will shape how nearly half the nation's healthcare tab gets spent over the next decade.
New CDC data show white women on average lived slightly shorter lives in 2014 compared to 2013. Most experts agreed it was a worrisome harbinger of what awaits other groups suffering the ill-effects of our increasingly unequal society.
The skeptics were out in force last week when the CMS launched a major expansion of its comprehensive primary-care initiative. They are way off base.
Ever heard of the “therapeutic illusion”? I hadn't until I read a Perspective article in last week's New England Journal of Medicine that should be required reading for any healthcare executive serious about moving his or her organization from volume-driven to value-based care.